A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.

Clinical trial NCT07679399 · RECRUITING

Trial details

NCT number: NCT07679399
Sponsor: Peking Union Medical College Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Biliary Tract Neoplasms Immunotherapy

Start date: 2025-06-01
Primary completion: 2027-01-01
Enrollment: 222

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.